Anti-CD19 CAR T Cells Preparation clinical trials
How each study uses Anti-CD19 CAR T Cells Preparation is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD19 CAR T Cells Preparation studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 16
The Children's Hospital of Zhejiang University School of Medicine (3) · Yan'an Affiliated Hospital of Kunming Medical University (2) · Shanghai GeneChem Co., Ltd. (2) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · Vinmec Research Institute of Stem Cell and Gene Technology (1) · Peking University Third Hospital (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Sheba Medical Center (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (1) · Anti-CD20 CAR T Cells Preparation (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-CD19 CAR T Cells Preparation.
- May 2027The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune DiseasesEarly Phase 1 · First Affiliated Hospital of Wenzhou Medical University
- Jul 2027Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ MalignanciesPhase 1 · University of Utah
Studies
Open first, then newest update. How each study uses Anti-CD19 CAR T Cells Preparation is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 20
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaRecruitingPhase 1C. Babis AndreadisNCT04545762Written as anti-CD19 CAR-T cellsHow we know
- Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune DiseasesNot yet recruitingPhase 1/2Peking University Third HospitalNCT06821659Written as anti-CD19 CAR-T cellsHow we know
- Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic DiseasesNot yet recruitingPhase 1Gustave Roussy, Cancer Campus, Grand ParisNCT07544225Written as anti-CD19 CAR-T cellsHow we know
- Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ MalignanciesRecruitingPhase 1University of UtahNCT06227026Written as Anti-CD19 CAR-T cellsHow we know
- A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell MalignanciesNot yet recruitingPhase 1/2Sheba Medical CenterNCT07503353Written as SHB-02-CD19 (anti CD19 CAR-T cells)How we know
- The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune DiseasesNot yet recruitingEarly Phase 1First Affiliated Hospital of Wenzhou Medical UniversityNCT06420154Written as anti-CD19-CAR-T cellsHow we know
- Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.RecruitingEarly Phase 1Shanghai Tongji Hospital, Tongji University School of MedicineNCT06375161Written as anti-CD19-CAR-T cellsHow we know
- CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility ProtocolRecruitingPhase 2KK Women's and Children's HospitalNCT05648019Written as Anti-CD19 CAR T-cellsHow we know
- Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic SclerosisSuspendedPhase 1The Children's Hospital of Zhejiang University School of MedicineNCT06792344Written as anti-CD19 CAR-T cellsHow we know
- Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNSWithdrawnPhase 1The Children's Hospital of Zhejiang University School of MedicineNCT06842589Written as anti-CD19 CAR-T cellsHow we know
- Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus ErythematosusActive, not recruitingPhase 1The Children's Hospital of Zhejiang University School of MedicineNCT06222853Written as anti-CD19-CAR-T cellsHow we know
- CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic LeukemiaCompletedPhase 1Vinmec Research Institute of Stem Cell and Gene TechnologyNCT06027957Written as anti-CD19 CAR T-cellsHow we know
- Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic LeukemiaStatus unknownPhase 1Yan'an Affiliated Hospital of Kunming Medical UniversityNCT04289220Written as Anti-CD19 CAR-T Cells InjectionHow we know
- CD19-targeting CAR T Cells for B Cell LymphomaWithdrawnPhase 1/2Fuda Cancer Hospital, GuangzhouNCT02547948Written as CD19-targeting CAR T Cells infusionHow we know
- CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic LeukemiaStatus unknownPhase 1Yan'an Affiliated Hospital of Kunming Medical UniversityNCT03854994Written as Anti-CD19 CAR-T Cells InjectionHow we know
- A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)Status unknownPhase 1Shanghai GeneChem Co., Ltd.NCT03030976Written as anti-CD19-CAR-T cellsHow we know
- CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownPhase 1/2PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT02819583Written as PCAR-019 (anti-CD19 CAR-T cells)How we know
- the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)Status unknownPhase 1/2Southwest Hospital, ChinaNCT02737085Written as Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cellsHow we know
- Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownPhase 1/2PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT02851589Written as PCAR-019 (anti-CD19 CAR-T cells)How we know
- A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell LeukemiaStatus unknownPhase 1/2Shanghai GeneChem Co., Ltd.NCT02672501Written as anti-CD19-CAR-T cellsHow we know
Given beside what is tested · 2 — Anti-CD19 CAR T Cells Preparation is usual care or a partner of the new treatment
- IVIG for Infection Prevention After CAR-T-Cell TherapyRecruitingPhase 2Fred Hutchinson Cancer CenterNCT05952804Written as Anti-CD19 CAR T Cells PreparationHow we know
- Chidamide Bridging for CAR-T TherapyRecruitingPhase 1/2Chinese PLA General HospitalNCT05370547Written as Anti-CD19 CAR-T cellsHow we know